Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Centre for Parasitology, Entomology and Malaria Control, Cambodia | OTHER |
| Institute Pasteur, Cambodia | UNKNOWN |
| World Health Organization | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In Cambodia, falciparum is becoming more difficult to treat because drugs are becoming less effective. The investigators can help to try to prevent the spread of this resistant malaria by adding a drug that will make it more difficult for the mosquito to drink up the malaria in people's blood. If the mosquito cannot drink up the malaria, then the malaria cannot develop in the mosquito so it will not be able to inject malaria back into people when it bites. The drug the investigators will use is called primaquine.
Primaquine commonly causes the red cells in the blood to break apart if they are weak. Red cells need enzymes to work properly and weak red cells have low amounts of an enzyme called glucose 6 phosphate dehydrogenase (G6PD). The investigators want to know if treating malaria with primaquine will be safe for the red cells. To do this study, the investigators need to know if a subject has low G6PD or not.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DHA PP plus primaquine, G6PD deficiency | Experimental | Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP. Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets. |
|
| DHA PP plus primaquine, G6PD normal | Active Comparator | Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP. Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets. |
|
| DHA PP alone, G6PD deficiency | Active Comparator | Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dihydroartemisinin piperaquine (DHA PP) | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Haemoglobin concentration | Compare haemoglobin concentrations in g/dL between the G6PD deficient arm given DHA PP plus primaquine, and the G6PD normal arm receiving the same regimen | Day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| Determine G6PD enzyme activity | Quantitative G6PD testing among all participants using the G6PD enzyme assay from Trinity Biologicals, USA, yielding G6PD enzyme results in U/g Hb. | Day 0 |
| Assess usefulness of field adapted WHO haemoglobin colour card vs. Hemocue |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dysoley Lek, MD | National Centre for Parasitology, Entomology and Malaria Control, Cambodia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ratanakiri Provincial Hospital | Ratanakiri | Ratanakiri | Cambodia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32179526 | Derived | Vantaux A, Kim S, Piv E, Chy S, Berne L, Khim N, Lek D, Siv S, Mukaka M, Taylor WR, Menard D. Significant Efficacy of a Single Low Dose of Primaquine Compared to Stand-Alone Artemisinin Combination Therapy in Reducing Gametocyte Carriage in Cambodian Patients with Uncomplicated Multidrug-Resistant Plasmodium falciparum Malaria. Antimicrob Agents Chemother. 2020 May 21;64(6):e02108-19. doi: 10.1128/AAC.02108-19. Print 2020 May 21. | |
| 30871496 |
| Label | URL |
|---|---|
| Malaria Consortium | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D016778 | Malaria, Falciparum |
| D005955 | Glucosephosphate Dehydrogenase Deficiency |
| ID | Term |
|---|---|
| D008288 | Malaria |
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D011319 | Primaquine |
| ID | Term |
|---|---|
| D000634 | Aminoquinolines |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
| Centers for Disease Control and Prevention |
| FED |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| DHA PP alone, G6PD normal | Active Comparator | Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP. |
|
| Primaquine | Drug |
|
Comparison of quantitative (HemoCue, g/dL HB) and qualitative (WHO haemolglobin colour card) estimates of haemoglobin concentration |
| Day 0 |
| Assess usefulness of rapid test for G6PDd in predicting acute intravascular haemolysis | Comparison of rapid G6PD test (AccessBio, USA) qualitative result against quantitative G6PD assay to determine predictive value for clinically significant haemolysis | Day 0 |
| Proportion patients with ≥25% change in haemoglobin as a marker of intravascular haemolysis | Comparing across all 4 arms: proportion of all patients with fractional change in haemoglobin ≥25% from day 0 to day 7 | Change from Day 0 to Day 7 |
| Plasma haemoglobin concentration as a marker of intravascular haemolysis | Comparing across all 4 arms: plasma haemoglobin concentration at day 7 | Day 7 |
| Urine colour change as a marker of intravascular haemolysis | Change in urine colour grade from day 0 to day 7 (Hillmen, Hall et al. 2004) | Change from Day 0 to Day 7 |
| Fractional change in haemoglobin as a marker of intravascular haemolysis | Comparing across all 4 arms: fractional change in haemoglobin on day 7 vs. day 0 | Change from Day 0 to Day 7 |
| Clearance rate of primaquine | Primaquine elimination clearance rate, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 |
| Half life of primaquine | Primaquine terminal elimination half life, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 |
| Primaquine volume of distribution | Primaquine apparent volume of distribution (Vd), modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 |
| Clearance rate of piperaquine | Piperaquine elimination clearance rate, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 |
| Half life of piperaquine | Piperaquine terminal elimination half life, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 |
| Piperaquine volume of distribution | Piperaquine apparent volume of distribution (Vd), modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 |
| Peak plasma concentration (Cmax) of primaquine | Cmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 |
| Peak plasma concentration (Cmax) of piperaquine | Cmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 |
| Time to primquine peak plasma concentration (Tmax) | Tmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 |
| Time to piperaquine peak plasma concentration (Tmax) | Tmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 |
| Area under the plasma concentration versus time curve - primaquine | Modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 |
| Area under the plasma concentration versus time curve - piperaquine | Modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 |
| Derived |
| Dysoley L, Kim S, Lopes S, Khim N, Bjorges S, Top S, Huch C, Rekol H, Westercamp N, Fukuda MM, Hwang J, Roca-Feltrer A, Mukaka M, Menard D, Taylor WR. The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians. BMC Infect Dis. 2019 Mar 12;19(1):250. doi: 10.1186/s12879-019-3862-1. |
| National Centre for Parasitology, Entomology and Malaria Control Program, Cambodia | View source |
| D000096724 |
| Mosquito-Borne Diseases |
| D000079426 | Vector Borne Diseases |
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D002239 | Carbohydrate Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D006571 | Heterocyclic Compounds |